Table 1. Baseline characteristics of UK Biobank participants who had no prior history of vascular disease and were not on lipid-lowering treatment, by sex (n = 306,654).
| Baseline characteristic | Female | Male | Total |
|---|---|---|---|
| Number of participants | 174,773 | 131,881 | 306,654 |
| Age at recruitment, years | 56.0 (7.9) | 55.9 (8.2) | 56.0 (8.0) |
| Cardiovascular risk factors | |||
| Current-smoker, percent | 9.3 | 11.7 | 10.3 |
| History of diabetes, percent | 0.8 | 1.7 | 1.2 |
| Treatment of hypertension, percent | 10.9 | 11.7 | 11.2 |
| Systolic blood pressure, mm Hg | 134.2 (18.6) | 140.4 (17.3) | 136.9 (19.1) |
| Total cholesterol, mmol/l | 6.0 (1.1) | 5.8 (1.0) | 5.9 (1.1) |
| HDL cholesterol, mmol/l | 1.6 (0.4) | 1.3 (0.3) | 1.5 (0.4) |
| LDL cholesterol, mmol/l | 3.7 (0.8) | 3.7 (0.8) | 3.7 (0.8) |
| C-reactive protein, Ln, mg/l | 0.3 (1.1) | 0.3 (1.0) | 0.3 (1.1) |
| Incident cardiovascular outcomes | |||
| Follow-up, years, median (5th–95th percentile) | 8.2 (6.8–9.4) | 8.1 (6.5–9.3) | 8.1 (6.8–9.4) |
| Number of coronary heart disease cases | 2,453 | 880 | 3,333 |
| Number of stroke cases | 1,311 | 1,036 | 2,347 |
Data are shown as mean (SD), unless otherwise stated, adjusted for UK Biobank study centre.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.